ReviewJournal of bioethical inquiry2018
Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer's Disease.
Review in Journal of bioethical inquiry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- From biomarker expansion to equitable implementation in mild cognitive impairment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- Presymptomatic Screening for Risks to Children's Mental Health : Ethical Considerations from a European Focus Group Study with Mental Health Professionals.Journal of bioethical inquiry · 2026Article
- Psychological impact of biomarker-assisted diagnosis of Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
- The Role of Blood-Based Biomarkers in Transforming Alzheimer's Disease Research and Clinical Management: A Review.International journal of molecular sciences · 2025Review
- Unresolved ethical questions of mHealth apps for Alzheimer's disease prevention.Medicine, health care, and philosophy · 2025Article
- Changing definitions of disease: Transformations in the diagnostic criteria for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study.Diagnostics (Basel, Switzerland) · 2025Article
- Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Review
- Establishing a machine learning dementia progression prediction model with multiple integrated data.BMC medical research methodology · 2024Article
- Psychological outcomes of dementia risk estimation in MCI patients: Results from the PreDADQoL project.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.Nature reviews. Neurology · 2024Review
- Validation of the "Perceptions Regarding pRE-Symptomatic Alzheimer's Disease Screening" (PRE-ADS) Questionnaire in the German Population: Attitudes, Motivations, and Barriers to Pre-Symptomatic Dementia Screening.Journal of Alzheimer's disease : JAD · 2024Article
- [Mild cognitive impairment in geriatric practice: patient orientation, diagnostics, treatment and ethics].Zeitschrift fur Gerontologie und Geriatrie · 2023Review
- Biomarkers of aging.Science China. Life sciences · 2023Review
- Developments in scalable strategies for detecting early markers of cognitive decline.Translational psychiatry · 2022Review
- Dementia risk communication. A user manual for Brain Health Services-part 3 of 6.Alzheimer's research & therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundToday, many healthcare or dementia organizations, clinicians, and companies emphasize the importance of detection of Alzheimer's disease in an early phase. This idea has gained considerable momentum due to the development of biomarkers, the recent FDA and EMA approval of three amyloid tracers, and the failure of a number of recent therapeutic trials conducted in the early dementia phase. On the one hand, an early etiological diagnosis can lead to early and more efficacious intervention. On the other hand, it is questioned how early an etiological diagnosis is beneficial to the patient. Here we consider ethical issues related to the process of biomarker testing and the impact on the diagnostic disclosure to patients with mild cognitive impairment due to prodromal Alzheimer's disease.
methodsA systematic review of the theoretical bioethics literature was performed by using electronic databases. The review was limited to articles published in English between 2003 and 2016.
resultsA total of twenty articles were included in our effort to make an analysis of the ethical challenges. One of the biggest challenges was the uncertainty and the predictive value of the biomarker-based diagnosis where patients can be amyloid positive without full certainty whether or when they will develop symptomatic decline due to Alzheimer's disease. Another challenge was the tension between the right to know versus the wish not to know, the limited efficacy of currently available treatment options, and the opportunities and consequences after receiving such an early diagnosis.
conclusionBased on the results and the additional comments in the discussion, several unanswered questions emerged. Therefore, careful consideration of all these ethical issues is required before the disclosure of a biomarker-based diagnosis to the patient with mild cognitive impairment due to Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.